Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX 03:32:43 2024-03-28 pm EDT 5-day change 1st Jan Change
284.9 USD -0.49% Intraday chart for Amgen Inc. +2.82% -1.13%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Amgen Presents New Research on Otezla at AAD 2024 CI
Amgen Keeps Q2 Dividend at $2.25 a Share, Payable June 7 to Stockholders of Record May 17 MT
Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024 CI
Transcript : Amgen Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM
Wall Street: horizontal consolidation CF
Stocks take a breather as key inflation data eyed RE
WallStreet: consolidates horizontally, US stats more mixed CF
Stocks stall as key inflation data awaited RE
Drugmakers deepen efforts to tap into booming market for obesity drugs RE
US STOCK-Wall Street wavers ahead of key inflation data RE
Amgen Opens Manufacturing Site in Central Ohio MT
Amgen Inc. Announces the Opening of Manufacturing Site in Central Ohio CI
Transcript : Amgen Inc. - Special Call
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... Our Logo
Amazon replaces Walgreens on Dow Jones index RE
Transcript : Amgen Inc. Presents at Oppenheimer 34th Annual Healthcare Life Sciences Conference, Feb-14-2024 12:00 PM
Eli Lilly partner BioAge raises $170 mln for obesity treatment RE
Global markets live: Amgen, Chipotle, Ford, Gilead, VF Corp... Our Logo
Abivax appoints new head of quality CF
Fed officials fail to convince investors, who are focused on earnings Our Logo
Oppenheimer Adjusts Amgen Price Target to $380 From $350, Maintains Outperform Rating MT
Dpa-AFX Overview: COMPANIES from 07.02.2024 - 15:15 DP
TD Cowen Adjusts Amgen Price Target to $370 From $336, Maintains Outperform Rating MT
Leerink Partners Downgrades Amgen to Market Perform From Outperform, Adjusts Price Target to $324 From $318 MT
Baird Adjusts Amgen Price Target to $215 From $185, Maintains Underperform Rating MT
Chart Amgen Inc.
More charts
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
286.3 USD
Average target price
304.8 USD
Spread / Average Target
+6.45%
Consensus
  1. Stock
  2. Equities
  3. Stock Amgen Inc. - Nasdaq
  4. News Amgen Inc.
  5. Barclays Adjusts Price Target on Amgen to $228 From $230, Maintains Equal-Weight Rating